Yep, I agree, but again that's one of the things Nadia and Steven were brought on board to avoid, a pr disaster like the pancreatic fiasco. Another one would be to neglect the dropping share price to the point where a dilution is needed, and I just don't think that's gonna happen on their watch.
As MultiTAA continues to produce positive results in trials, it moves closer to truly being the go-to treatment for several cancers. Take it to the bank that big pharma is well aware of MRKR, even for a delivery system for their own drugs, and soon they'll make the bosses a offer they can't refuse.
News 
Market Data 
Discover 
